ML-7

Details

Stereochemistry	ACHIRAL
Molecular Formula	C15H17IN2O2S
Molecular Weight	416.277
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

IC1=CC=CC2=C1C=CC=C2S(=O)(=O)N3CCCNCC3

InChI

InChIKey=GEHJIACZUFWBTK-UHFFFAOYSA-N

InChI=1S/C15H17IN2O2S/c16-14-6-1-5-13-12(14)4-2-7-15(13)21(19,20)18-10-3-8-17-9-11-18/h1-2,4-7,17H,3,8-11H2

HIDE SMILES / InChI

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/3108259

1-(5-iodonaphthalene-1-sulfonyl)-1H-hexahydro-1,4-diazepine (ML-7) is an inhibitor of myosin light chain kinase (MLCK). It is widely used to study MLCK signaling both in vitro and in vivo.

CNS Activity

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Myosin light chain kinase, smooth muscle 6 Target ID: CHEMBL3062 Sources: https://www.ncbi.nlm.nih.gov/pubmed/3108259	Inhibitor 8297		0.3 µM [Ki]

Conditions

Condition	Modality	Highest Phase	Product
Nonalcoholic steatohepatitis 9 Sources: https://www.ncbi.nlm.nih.gov/pubmed/26080824	Primary	Preclinical	Unknown Approved Use Unknown
Atherosclerosis 74 Sources: https://www.ncbi.nlm.nih.gov/pubmed/26096176	Primary	Preclinical	Unknown Approved Use Unknown
Ischemia 16 Sources: https://www.ncbi.nlm.nih.gov/pubmed/28930548 https://www.ncbi.nlm.nih.gov/pubmed/26992120 https://www.ncbi.nlm.nih.gov/pubmed/25920934	Primary	Preclinical	Unknown Approved Use Unknown

PubMed

Title	Date	PubMed
Diphosphorylation of platelet myosin ex vivo in the initial phase of activation by thrombin.	1992 Jul 22	1643115
Differentiation of human monoblastic leukemia U937 cells induced by inhibitors of myosin light chain kinase and prevention of differentiation by granulocyte-macrophage colony-stimulating factor.	1993 Apr 16	8471626
Role of myosin phosphorylation and [Ca2+]i in myogenic reactivity and arteriolar tone.	1995 Nov	7503253
Naphthalenesulphonamides block neutrophil superoxide production by intact cells and in a cell-free system: is myosin light chain kinase responsible for these effects?	1995 Oct 1	7575484
ML-7 and W-7 facilitate thromboxane A2-mediated Ca2+ mobilization in rabbit platelets.	1996 Mar 7	8867106
Inhibition of sandfly fever Sicilian virus (Phlebovirus) replication in vitro by antiviral compounds.	1997 Sep-Oct	9403935
Role of rho-kinase activity in angiotensin II-induced contraction of rabbit clitoral cavernosum smooth muscle.	2002 Dec	12494280
Degranulation in RBL-2H3 cells: regulation by calmodulin pathway.	2003	14499669
The specificities of protein kinase inhibitors: an update.	2003 Apr 1	12534346
PAF- and bradykinin-induced hyperpermeability of rat venules is independent of actin-myosin contraction.	2003 Jul	12649070
Myofibrillogenesis in the first cardiomyocytes formed from isolated quail precardiac mesoderm.	2003 May 15	12729566
Functional diversity between Rho-kinase- and MLCK-mediated cytoskeletal actions in a myofibroblast-like hepatic stellate cell line.	2003 May 30	12745062
The catalytic domain of xPAK1 is sufficient to induce myosin II dependent in vivo cell fragmentation independently of other apoptotic events.	2003 Nov 15	14597201
Role of the actin cytoskeleton in regulating endothelial permeability in venules.	2003 Oct	14557824
Myosin II is present in gastric parietal cells and required for lamellipodial dynamics associated with cell activation.	2003 Sep	12724136
Modulation of acto-myosin contractility in skeletal muscle myoblasts uncouples growth arrest from differentiation.	2004 Aug 1	15252113
Myosin-mediated cytoskeleton contraction and Rho GTPases regulate laminin-5 matrix assembly.	2004 Feb	14691950
Aluminium causes variable responses in actin filament cytoskeleton of the root tip cells of Triticum turgidum.	2005 Oct	16228895
Myosin 2 is a key Rho kinase target necessary for the local concentration of E-cadherin at cell-cell contacts.	2005 Oct	16030252
Actin and non-muscle myosin II facilitate apical exocytosis of tear proteins in rabbit lacrimal acinar epithelial cells.	2005 Oct 15	16219687
Thrombin-induced contraction in alveolar epithelial cells probed by traction microscopy.	2006 Aug	16675616
Inhibiting myosin light chain kinase retards the growth of mammary and prostate cancer cells.	2006 May	16574402
Organized migration of epithelial cells requires control of adhesion and protrusion through Rho kinase effectors.	2007 Mar	17138966
Myosin light chain kinase-independent inhibition by ML-9 of murine TRPC6 channels expressed in HEK293 cells.	2007 Sep	17603544
Myosin phosphorylation triggers actin polymerization in vascular smooth muscle.	2008 Nov	18835913
[Protective effect of myosin light-chain kinase inhibitor on acute lung injury].	2009 Apr	19374788
Inhibition of myosin light chain phosphorylation decreases rat mesenteric lymphatic contractile activity.	2009 Aug	19525378
MDR1 function is sensitive to the phosphorylation state of myosin regulatory light chain.	2010 Jul 16	20510202
Murine vasa recta pericyte chloride conductance is controlled by calcium, depolarization, and kinase activity.	2010 Nov	20686172

Sample Use Guides

In Vivo Use Guide

The rabbits were fed a high‑fat diet supplemented with 1 mg/kg/day ML7. Rats: 1 mg/kg ML-7 i.p.

Route of Administration: Other

In Vitro Use Guide

1-(5-iodonaphthalene-1-sulfonyl)-1H-hexahydro-1,4-diazepine hydrochloride (ML-7), induced Nitroblue tetrazolium reducing activity, lysozyme activity and morphological maturation of human monoblastic U937, THP-1 and promyelocytic HL-60 cells, but not of erythroblastic K562 cells. 40 uM ML-7 induces activation of caspase-3 in adherent MCF-10A and MCF-10A Ras-transformed cells.

Name

Type

Language

ML-7

Common Name

English

1H-1,4-DIAZEPINE, HEXAHYDRO-1-((5-IODO-1-NAPHTHALENYL)SULFONYL)-

Systematic Name

English

NSC-734550

Code

English

Code System Code Type Description

FDA UNII

E2C2LB77BF